Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in-Human Study of IK-930, an Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors

NCT05228015 is registered in ClinicalTrials.gov with Ikena Oncology as lead sponsor.

NCT NCT05228015
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05228015 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in-Human Study of IK-930, an Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors
Lead sponsor
Ikena Oncology
Phase
Phase 1
Overall status
Terminated
Start date
January 7, 2022
Completion date
September 9, 2024
Enrollment
67 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

epithelioid hemangioendothelioma (ehe), malignant pleural mesothelioma (mpm), nf2 deficiency, nf2 deficient mesothelioma, other nf2 deficient solid tumors and solid tumors with yap1/taz fusion genes, solid tumor, solid tumors, adult, yap1 or taz gene fusions